Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 20 Aug 2026 for Acrivon Therapeutics, Inc., €175. Read the official filing
Filing timeline
BuySaleKatharine Peterson
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Katharine Peterson: trading record in brief
All filings by Katharine Peterson on record concern Acrivon Therapeutics, Inc. In total, 9 filings cover trades dated from 14 May 2024 to 18 August 2026.
Sales make up the whole of the open-market record (1 sale, €175). Besides market trades, the filings include 8 share grants. So far in 2026, the count stands at no purchases and 1 sale.
The newest entry dates from 20 August 2026: an open-market sale of €175, in Acrivon Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Katharine Peterson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations9 total
101 shares@ US$2.01Common StockSEC:0000905148-26-003840:0
116 shares@ US$1.634.8% of flowCommon StockSEC:0000905148-26-000939:0
99 shares@ US$2.246.3% of flowCommon StockSEC:0000905148-25-004131:0
99 shares@ US$1.393.8% of flowCommon StockSEC:0000905148-25-003043:0
99 shares@ US$1.143.3% of flowCommon StockSEC:0000905148-25-001824:0
116 shares@ US$5.4219.8% of flowCommon StockSEC:0000905148-25-000730:0
99 shares@ US$7.9224.5% of flowCommon StockSEC:0000905148-24-003228:0
99 shares@ US$7.0220.8% of flowCommon StockSEC:0000905148-24-002283:0
99 shares@ US$8.3625.2% of flowCommon StockSEC:0000905148-24-001495:0
9 of 9 declarations
